- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
EP. 2A: Treatment Challenges and Unmet Needs in Extensive-Stage Small Cell Lung Cancer
October 18, 2021
Dr. Jared Weiss of the University of North Carolina Lineberger Comprehensive Cancer Center considers treatment challenges and unmet needs in the current standard of care management of extensive-stage small cell lung cancer.
Bevacizumab Biosimilar Prolongs PFS in NonSquamous NSCLC
October 18, 2021
In combination with chemotherapy and sintilimab, a bevacizumab biosimilar injection was found to increase PFS in patients with Nonsquamous NSCLC who progressed after a prior EGFR-TKI.
Modern Approaches to Treating Neuroendocrine Tumors
October 18, 2021
Eileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.
New Mechanisms Under Study to Overcome Osimertinib Resistance in EGFR+ NSCLC
October 18, 2021
Although osimertinib has been shown to overcome T790M-mediated mutations in the second-line setting, as with other EGFR tyrosine kinase inhibiors progression on osimertinib is inevitable.
The Future of Metastatic Castrate-Resistant Prostate Cancer Management
October 18, 2021
An expert discusses the future of metastatic castrate-resistant prostate cancer management.
The ODENZA Trial: Metastatic Castrate-Resistant Prostate Cancer
October 18, 2021
Karim Fizazi, MD, PhD, reviews darolutamide data in prostate cancer, including data from phase II clinical trial, ODENZA.
Darolutamide in Metastatic Castrate-Resistant Prostate Cancer
October 18, 2021
A key opinion leader discusses impact of ADTs on brain and cognitive function in men with prostate cancer.
Metastatic Castrate-Resistant Prostate Cancer: Androgen Receptor Inhibitors
October 18, 2021
Dr. Karim Fizazi describes the use of next generation androgen receptor inhibitors in treatment of metastatic castrate-resistant prostate cancer.
Systemic Therapy Options in Metastatic Castrate-Resistant Prostate Cancer
October 18, 2021
An oncologist explains treatment selection and the systemic therapy options available for patients with metastatic castrate-resistant prostate cancer.
An Overview of Metastatic Castrate-Resistant Prostate Cancer
October 18, 2021
Karim Fizazi, MD, PhD, provides an overview of advances in treatment of metastatic castrate-resistant prostate cancer.
Improved Sensitivity, Monitoring Needed for MRD in Adult and Pediatric ALL
October 18, 2021
Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.
Improving Risk/Benefit of Frontline Classical Hodgkin Lymphoma Treatment
October 17, 2021
Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.